Innova Captab Q1 FY27: Revenue up 34%, PAT up 42% YoY; FY26 results under revision
INNOVACAP · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.0 pts less than Nifty Microcap 250 and 0.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Innova Captab reported Q1 FY27 consolidated revenue of Rs 4,708.5 million, up 33.9% YoY from Rs 3,515.4 million. Consolidated PAT rose 42.3% to Rs 441.3 million from Rs 310.2 million. Standalone revenue grew 39.6% to Rs 4,004.8 million; standalone PAT up about 58% to Rs 320.6 million. EPS stood at Rs 7.71 consolidated versus Rs 5.42. Auditors B S R and Co LLP gave an unmodified review. Board also flagged inadvertent errors in FY26 financial statements being corrected, with no material impact on Q1 results.
Strong Q1 beat on revenue and profit growth signals healthy pharma demand. Pending FY26 revision is a minor watchpoint but flagged as immaterial.